10 results about "Colicin" patented technology

The invention belongs to the field of biological medicine, and particularly relates to an information rhzomorph array for resisting small cell lung cancer and application of the information rhzomorph array. The invention provides polypeptides with amino acid sequences as shown in SEQ ID NO: 1-30. The invention also provides a medicine for resisting small cell lung cancer. The medicine comprises fusion protein obtained by respectively connecting the channel structural domain of the coliform and the polypeptide with the amino acid sequence shown as SEQ ID NO: 1-30. Pharmacodynamic experiments prove that in each growth cycle, a mouse tumor-bearing model always cannot get rid of the recognition and killing of an information rhzomorph array composed of thirty fusion proteins on tumors. A guinea pig model experiment proves that no toxic or side effect is generated in an animal model when the information rhzomorph array is continuously used for 30 days. The information rhzomorph array can be used as an effective small cell lung cancer treatment medicine.

The invention discloses a multi-omics non-invasive intestinal cancer risk assessment method based on pks + intestinal bacteria, cancer driver genes and methylated molecular clocks, which comprises the steps of excrement DNA sample extraction, primer design and screening, triple specificity verification, non-invasive detection and multi-omics quantitative scoring model, and detection of pks + escherichia coli in excrement. The pks + Escherichia coli can synthesize cytotoxin colicin, induce DNA double-chain breakage and chromosome instability in host cells, cause cell cycle arrest and finally cause cell death, key information can be provided for cancer prevention, diagnosis and precise treatment, and the application has the advantages that the application is wide in application range and high in practicability. In addition, deep understanding of the key cancer driver gene of the intestinal cancer is helpful for studying the occurrence and development mechanism of the intestinal cancer, a new therapeutic target can be provided for the intestinal cancer, new possibilities are provided for early discovery, risk assessment and monitoring of the intestinal cancer, the screening accuracy and sensitivity are further improved, and the screening method is suitable for popularization and application. And the method has the advantage of higher accuracy in risk assessment of intestinal cancer.

The application belongs to the field of biological medicine, and particularly relates to an information bacteriocin array against small cell lung cancer and application thereof. Amino acid sequences such as SEQ ID NO: 1-30 are provided. A drug against small cell lung cancer is also provided, which comprises a fusion protein obtained by connecting a channel domain of colicin with polypeptides with amino acid sequences such as SEQ ID NO: 1-30. Pharmacodynamics experiments prove that in each growth cycle, a mouse tumor-bearing model cannot escape the recognition and killing of the information bacteriocin array composed of thirty kinds of fusion proteins. Guinea pig model experiments prove that the continuous use of the information bacteriocin array for 30 days does not produce any toxic side effects in the animal model. The information bacteriocin array can be used as an effective drug for treating small cell lung cancer.

The application belongs to the field of biological medicine, and relates to an anti-tumor pheromone array and application thereof. A polypeptide composition is provided, which comprises forty-six polypeptides, and the amino acid sequences of the forty-six polypeptides are shown as SEQ ID NO:1-46. An anti-tumor drug is also provided, which comprises forty-six fusion proteins, and the forty-six fusion proteins are obtained by connecting the channel forming domain of colicin with the forty-six polypeptides with the amino acid sequences shown as SEQ ID NO:1-46. Experiments prove that the pheromone array composed of the forty-six fusion proteins shows extremely significant growth inhibition and killing effects on pancreatic cancer cells and liver cancer cell-derived tumor models, and does not have any toxic side effects.

The present invention belongs to the field of biomedicine, and specifically relates to a pheromonicin array against small cell lung cancer and the use thereof. Provided is a polypeptide having an amino acid sequence as shown in SEQ ID NOs: 1-30. Further provided is a drug against small cell lung cancer, which contains a fusion protein obtained by means of respectively connecting the channel domain of colicin to the polypeptide having the amino acid sequence as shown in SEQ ID NOs: 1-30. Pharmacodynamic experiments confirm that in each growth cycle, a tumor-bearing mouse model cannot escape the recognition and killing of tumors by the pheromonicin array consisting of 30 fusion proteins. Guinea pig model experiments confirm that the continuous use of the pheromonicin array for 30 days does not produce any toxic side effects in the animal model. The pheromonicin array can be used as an effective drug for treating small cell lung cancer.

The present invention belongs to the field of biomedicine, and specifically relates to a pheromonicin array against small cell lung cancer and the use thereof. Provided is a polypeptide having an amino acid sequence as shown in SEQ ID NOs: 1-30. Further provided is a drug against small cell lung cancer, which contains a fusion protein obtained by means of respectively connecting the channel domain of colicin to the polypeptide having the amino acid sequence as shown in SEQ ID NOs: 1-30. Pharmacodynamic experiments confirm that in each growth cycle, a tumor-bearing mouse model cannot escape the recognition and killing of tumors by the pheromonicin array consisting of 30 fusion proteins. Guinea pig model experiments confirm that the continuous use of the pheromonicin array for 30 days does not produce any toxic side effects in the animal model. The pheromonicin array can be used as an effective drug for treating small cell lung cancer.

The invention relates to the technical field of zymomonas mobilis, in particular to an engineering strain of zymomonas mobilis, compound protein and a method. The engineering strain is zymomonas mobilis containing genes for coding exo-glucanase, coding endoglucanase, coding beta-glucosidase, coding colicin E protein and coding protein with affinity interaction with the colicin E protein. The engineering strain can efficiently express exoglucanase, endoglucanase, beta-glucosidase, Escherichia coli E protein and protein with affinity interaction with the Escherichia coli E protein, is beneficial to forming a compound enzyme assembly, improves the enzyme activity of cellulose hydrolysis and the yield of glucose, reduces the energy consumption of cellulose hydrolysis, and improves the yield of glucose. The method has very important industrial application value.

The invention relates to the technical field of pathogenic bacteria and vaccines thereof, in particular to a sheep-derived A2-type mannheimia haemolytica strain, a vaccine and application. The invention discloses a sheep-derived A2 type mannheimia haemolytica strain, and the preservation number of the sheep-derived A2 type mannheimia haemolytica strain is CGMCC According to the bacterial strain, due to gene frame-shift mutation, protein translation is terminated in advance, so that the protein truncation of the colicin transporter is caused. The characteristics can be utilized to realize the specificity test of the strain and be used for evaluating the immune effect of the vaccine. The aluminum hydroxide gel vaccine is prepared by optimizing a fermentation process and a concentration process and performing vaccine compatibility after inactivation. Safety tests show that the vaccine has good safety to sheep. Efficacy tests prove that the vaccine has a good protection effect on challenge after mice and sheep are immunized, and the protection rate can reach 80% or above. According to the technical scheme, the technical problem that the mannheimia haemolytica A2 type vaccine for sheep is lacked in the prior art can be solved, and the mannheimia haemolytica A2 type vaccine has a good popularization prospect.

The present invention discloses a dCE-KOD DNA polymerase and a preparation method and application thereof. The dCE-KOD DNA polymerase is obtained by fusing a mutant dCE expressing colicin CE at the N-terminus of a KOD DNA polymerase protein sequence, wherein dCE is any one of dCE2, dCE7, dCE8 and dCE9. Compared with natural KOD DNA polymerase, the continuous synthesis ability of dCE-KOD DNA polymerase is effectively improved and it has higher sensitivity to templates. Therefore, the dCE-KOD DNA polymerase provided by the present invention has broad application prospects in gene cloning, high-fidelity amplification of long fragments and PCR diagnosis.

The present invention discloses a highly progressive Pfu DNA polymerase and a preparation method and application thereof, wherein the highly progressive Pfu DNA polymerase is specifically: a mutant dCE expressing colicin CE is fused to the N-terminus of a wild-type Pfu DNA polymerase protein sequence, wherein the gene sequence of dCE is shown in any one of SEQ ID NO.2‑5. Compared with the wild-type Pfu DNA polymerase, the amplification speed of the modified polymerase can reach about 8 kb / min, which is much higher than the wild-type Pfu DNA polymerase, and the amplification yield is also significantly improved. Therefore, the highly progressive Pfu DNA polymerase provided by the present invention has broad application prospects in gene cloning, high-fidelity amplification of long fragments, and PCR diagnosis.